Stelara 130 mg IV Infusion (Ustekinumab): Complete Clinical Guide to Induction Dosing, Preparation Protocols & Safety Monitoring

[Insert Stelara 130 mg IV Vial Product Image Here]

1. What is Stelara 130 mg IV (Ustekinumab Intravenous)?

Stelara represents one of the most significant advances in targeted immunomodulatory therapy for inflammatory bowel disease (IBD) over the past decade. Its active pharmaceutical ingredient, ustekinumab, is a fully human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody produced through recombinant DNA technology in a murine myeloma cell line (Sp2/0). Unlike conventional broad-spectrum immunosuppressants that blunt the entire immune response, ustekinumab operates with remarkable precision by binding exclusively to the p40 protein subunit shared by two pro-inflammatory cytokines: interleukin-12 (IL-12) and interleukin-23 (IL-23).

It is critically important for clinicians and patients alike to understand that Stelara is available in two fundamentally distinct pharmaceutical presentations, each serving a different phase of the treatment pathway:

• Stelara 130 mg / 26 mL IV Concentrate (the focus of this guide): This single-use vial contains a concentrated solution that must be diluted in normal saline and administered exclusively via intravenous infusion in a hospital or accredited day-care unit. It is never injected subcutaneously. The IV formulation serves as the one-time induction loading dose designed to rapidly achieve therapeutic serum concentrations, overwhelm the inflammatory cytokine cascade, and initiate mucosal healing in the gastrointestinal tract of patients with active Crohn’s disease or ulcerative colitis.
• Stelara Pre-filled Syringes (45 mg and 90 mg SC): These ready-to-use subcutaneous injections serve dual purposes. In dermatology and rheumatology, they are used from the outset for plaque psoriasis and psoriatic arthritis. In gastroenterology, they become the long-term maintenance therapy that patients self-administer at home every 8 or 12 weeks following completion of the initial IV induction dose.

Manufactured by Janssen Biotech, a subsidiary of Johnson & Johnson, Stelara holds marketing authorisations from the US FDA, the European Medicines Agency (EMA), and multiple national regulatory authorities across the Middle East and North Africa. For a comprehensive overview of biologic therapies available in the region, visit the Pharma Guide Drug Index.

2. Detailed Composition & Mechanism of Action

Each Stelara 130 mg vial delivers 26 mL of a clear, colourless-to-light-yellow sterile concentrate at a concentration of 5 mg/mL ustekinumab. The formulation is free from pyrogens and contains no antimicrobial preservatives, underscoring the requirement for single-use aseptic handling. The complete excipient profile is outlined below:

Molecular Pharmacology: Dual Cytokine Neutralisation

The elegance of ustekinumab’s mechanism lies in its ability to disrupt two parallel inflammatory pathways with a single molecular interaction. By binding with high affinity to the p40 subunit — a protein component common to both IL-12 and IL-23 — ustekinumab prevents these cytokines from docking onto their shared receptor (IL-12Rβ1) expressed on the surface of T-lymphocytes and natural killer cells. The downstream consequences are profound:

1. Suppression of the Th1 axis (IL-12 blockade): IL-12 normally drives naïve CD4+ T-cells to differentiate into T-helper type 1 (Th1) effector cells, which secrete interferon-gamma (IFN-γ) and promote granulomatous inflammation characteristic of Crohn’s disease. Ustekinumab effectively silences this cascade.
2. Suppression of the Th17 axis (IL-23 blockade): IL-23 is essential for the survival and expansion of Th17 cells, the principal producers of IL-17A and IL-22 — cytokines that recruit neutrophils and drive tissue destruction in the intestinal mucosa. Blocking IL-23 starves these pathogenic cells of their survival signal.

The net clinical result is a comprehensive yet targeted dampening of the intestinal inflammatory storm, permitting endoscopic mucosal healing without the profound global immunosuppression associated with older biologic classes. This dual-pathway inhibition is what distinguishes ustekinumab from anti-TNF agents (which target a single cytokine) and from newer selective IL-23p19 inhibitors (which leave the IL-12/Th1 pathway intact).

3. Clinical Indications & Therapeutic Uses

The 130 mg IV formulation of Stelara carries regulatory approval specifically for the induction phase of treatment in adult patients (≥18 years) with the following conditions:

• Moderately-to-Severely Active Crohn’s Disease (CD): Indicated for patients who have demonstrated an inadequate response, loss of response, or intolerance to conventional therapies including corticosteroids, immunomodulators (azathioprine, 6-mercaptopurine, methotrexate), or prior anti-TNF biologics (infliximab, adalimumab, certolizumab). Clinical trial data from the UNITI-1 and UNITI-2 programmes demonstrated that a single IV ustekinumab infusion achieved clinical response in approximately 34–56% of patients by week 6, with significant improvements in stool frequency, abdominal pain scores, and C-reactive protein levels. The therapy promotes fistula closure and reduces the need for surgical bowel resection.
• Moderately-to-Severely Active Ulcerative Colitis (UC): Approved for adults experiencing persistent rectal bleeding, urgency, and mucosal ulceration despite optimised aminosalicylate therapy (mesalazine, sulfasalazine) or prior biologic failure. The UNIFI induction trial established that IV ustekinumab induced clinical remission in roughly 15–19% of biologic-experienced UC patients by week 8, with endoscopic improvement observed in a substantially higher proportion. For many patients, this therapy offers a viable alternative to colectomy.

4. Dosage Regimens & Administration Guidelines

Weight-Based Induction Dosing Schedule

The IV induction dose of Stelara is calculated to deliver approximately 6 mg per kilogram of body weight. Because each vial contains a fixed 130 mg of ustekinumab, the number of vials required is determined by the patient’s actual body weight at the time of infusion, as detailed in the following tiered dosing table:

Aseptic Preparation Protocol

Proper preparation is essential to maintain protein integrity and patient safety. The following steps must be performed by a qualified pharmacist or trained nurse in a controlled environment:

1. Visually inspect each vial. The solution should appear clear and colourless to faintly yellow. Discard any vial exhibiting turbidity, discolouration, or visible particulate matter.
2. Obtain a 250 mL infusion bag of 0.9% sodium chloride (normal saline). Do not use dextrose-containing solutions or other diluents.
3. Volume displacement step (mandatory): Withdraw and discard a volume of saline from the bag equal to the total volume of drug concentrate to be added. For example, if three vials (78 mL total) are required, remove 78 mL of saline first so the final bag volume remains approximately 250 mL.
4. Slowly withdraw the concentrate from each vial and inject it into the saline bag.
5. Gently invert the bag several times to achieve homogeneity. Never shake the bag vigorously, as mechanical agitation can denature the monoclonal antibody and generate protein aggregates or foam.

Infusion Administration & Monitoring

• Administer the diluted solution through an IV infusion set equipped with an in-line, sterile, non-pyrogenic, low-protein-binding filter with a pore size of 0.2 to 0.22 micrometres.
• The infusion must be delivered over a minimum duration of 60 minutes (1 hour) at a constant rate.
• Do not co-administer any other medications through the same IV line during the Stelara infusion.
• Monitor vital signs (blood pressure, heart rate, respiratory rate, temperature) continuously throughout the infusion and for at least one hour post-completion to detect any acute hypersensitivity or infusion-related reactions.

Transition to Subcutaneous Maintenance

Exactly 8 weeks after the IV induction infusion, the patient receives the first maintenance dose of Stelara 90 mg via subcutaneous injection (pre-filled syringe). Subsequent maintenance injections of 90 mg are administered every 8 weeks or every 12 weeks, depending on the individual clinical response and the treating gastroenterologist’s assessment. This two-phase approach — a single hospital visit for IV loading followed by convenient home-based SC dosing — is one of the principal practical advantages of the ustekinumab regimen. Explore additional therapeutic protocols in the Comprehensive Drug Index on Pharma Guide.

5. Adverse Drug Reactions & Contraindications

Ustekinumab generally demonstrates a favourable safety profile relative to anti-TNF biologics, but its immunomodulatory effects necessitate vigilant monitoring throughout therapy. Adverse events are categorised below by frequency and clinical significance:

Common Adverse Reactions (≥ 1% to < 10%)

• Infusion-related reactions: Headache, nausea, dizziness, flushing, pruritus, and transient blood pressure fluctuations occurring during or within hours of the IV infusion (reported in approximately 1–3% of patients).
• Upper respiratory tract infections: Nasopharyngitis, sinusitis, and pharyngitis are the most frequently reported infectious complications.
• Fatigue and arthralgia: Non-specific constitutional symptoms that typically resolve without intervention.
• Injection-site reactions (during SC maintenance phase): Erythema, mild pain, or bruising at the subcutaneous injection site.

Uncommon but Clinically Significant Risks (< 1%)

• Serious infections: Reactivation of latent tuberculosis (pulmonary and extrapulmonary), invasive fungal infections (candidiasis, histoplasmosis), and herpes zoster (shingles). Pre-treatment screening for TB and hepatitis B/C is mandatory.
• Reversible Posterior Leukoencephalopathy Syndrome (RPLS / PRES): An extremely rare but potentially life-threatening neurological emergency characterised by severe headache, seizures, visual disturbances, and altered mental status. Immediate drug discontinuation and urgent brain MRI are required.
• Non-infectious interstitial pneumonitis: Progressive dyspnoea and dry cough warranting chest imaging and pulmonary evaluation.
• Malignancy risk: As with all biologic immunosuppressants, long-term surveillance data suggest a theoretical increase in non-melanoma skin cancers. Annual dermatological screening is recommended.

Absolute Contraindications

• Known hypersensitivity to ustekinumab or any excipient in the formulation.
• Active, clinically significant infection (including active tuberculosis, sepsis, or opportunistic infections).
• Concurrent administration of live attenuated vaccines.

6. Drug Interactions & Dietary Precautions

• Live Attenuated Vaccines (Absolute Prohibition): Vaccines containing live organisms — including MMR (measles, mumps, rubella), varicella, yellow fever, BCG, oral polio (OPV), and live-attenuated influenza (LAIV) — must not be administered during Stelara therapy and for at least 12 months following the last dose. Inactivated vaccines (injectable influenza, pneumococcal, hepatitis B, inactivated COVID-19 vaccines) are considered safe, although the antibody response may be suboptimal due to immunomodulation.
• Concurrent Biologic Therapies: Combining ustekinumab with other biologic agents (anti-TNF drugs such as infliximab or adalimumab, anti-integrins such as vedolizumab, or JAK inhibitors such as tofacitinib) is not recommended outside of controlled clinical trial settings due to the compounded risk of severe immunosuppression and opportunistic infections.
• CYP450 Substrate Considerations: While ustekinumab is not a direct inhibitor or inducer of cytochrome P450 enzymes, the resolution of systemic inflammation can normalise hepatic CYP activity that was previously suppressed by elevated cytokine levels. Consequently, serum concentrations of narrow therapeutic index drugs metabolised by CYP pathways (warfarin, phenytoin, cyclosporine, theophylline) may shift as inflammation resolves, necessitating therapeutic drug monitoring and potential dose adjustments.
• Food and Dietary Interactions: No clinically relevant food-drug interactions have been identified with ustekinumab. The IV formulation bypasses gastrointestinal absorption entirely, and the SC maintenance doses are not affected by meal timing or composition.

7. Special Populations & Clinical Considerations

• Pregnancy (FDA Category: Not formally assigned — IgG1 placental transfer documented): Ustekinumab, like all IgG1 monoclonal antibodies, actively crosses the placenta via FcRn-mediated transport, particularly during the second and third trimesters. Global pregnancy registries have not identified a consistent pattern of teratogenicity; however, uncontrolled IBD itself poses substantial risks of preterm delivery, low birth weight, and maternal complications. The prevailing clinical consensus supports continuation of therapy when the benefit of maintaining disease remission outweighs the theoretical fetal risk. If the infant was exposed in utero during the third trimester, live vaccines (notably BCG) should be deferred for at least 6 months after birth. For more on reproductive health considerations, consult the Sexual & Reproductive Health Hub.
• Lactation: Minimal quantities of ustekinumab have been detected in human breast milk. Given the molecule’s large protein structure, it is largely degraded in the infant’s gastrointestinal tract and is unlikely to reach systemic circulation in pharmacologically meaningful amounts. Most expert guidelines consider breastfeeding compatible with ustekinumab therapy when clinically necessary.
• Paediatric Patients (< 18 years): The safety and efficacy of the 130 mg IV induction formulation have not been established in the paediatric population for Crohn’s disease or ulcerative colitis. Paediatric IBD management should follow age-appropriate protocols under specialist supervision.
• Geriatric Patients (≥ 65 years): Pharmacokinetic analyses have not revealed age-related differences in ustekinumab clearance or efficacy. However, elderly patients carry a higher baseline risk of serious infections and malignancy, warranting enhanced surveillance during therapy.
• Renal & Hepatic Impairment: Monoclonal antibodies are catabolised via the reticuloendothelial system into amino acids and peptides rather than being excreted renally or hepatically. No dose adjustments are anticipated for patients with mild-to-moderate organ dysfunction, although formal pharmacokinetic studies in severe impairment remain limited.

8. Generic Equivalents & Therapeutic Alternatives

While no biosimilar versions of ustekinumab have received widespread approval as of the current regulatory cycle, several alternative biologic agents are available for the management of moderate-to-severe IBD. The following comparison table highlights the principal therapeutic options:

The choice between these agents depends on disease phenotype, prior treatment history, comorbidity profile, patient preference, and regional formulary availability. Dr. Ahmad Baker and the Pharma Guide clinical team can help you navigate these complex therapeutic decisions.

9. Regional Availability & Authentication Guide

Stelara 130 mg IV vials are distributed across the MENA and GCC regions through authorised pharmaceutical importers under strict cold-chain protocols. Key acquisition and storage considerations include:

• Regulatory Pricing: In the Egyptian market, the officially registered price for a single 130 mg / 26 mL vial is approximately 53,000 EGP. Given that the induction dose requires 2 to 4 vials depending on body weight, the total cost of the initial IV infusion can range from 106,000 to 212,000 EGP. The 90 mg SC maintenance syringe is priced at approximately 37,157 EGP per unit. Prices are subject to periodic revision by national drug pricing authorities.
• Insurance & Government Coverage: In many MENA countries, biologic therapies for IBD are covered through national health insurance schemes, specialised medical council approvals (e.g., treatment at state expense), or manufacturer-sponsored patient support programmes (PSPs). Pre-authorisation typically requires endoscopic documentation of disease severity and evidence of prior conventional therapy failure.
• Cold-Chain Integrity: Stelara vials must be stored exclusively in a monitored refrigerator at 2°C to 8°C. Freezing is absolutely prohibited — even a single freeze-thaw cycle irreversibly denatures the antibody and renders the product clinically inert and potentially immunogenic. Vials should remain in their original outer carton to protect from light exposure.
• Counterfeit Prevention: Always verify the GTIN barcode, serial number, batch/lot number, and expiry date printed on the carton against the authorised distributor’s records. Inspect tamper-evident seals before use. Report any suspicious packaging to the local regulatory authority and the manufacturer’s regional pharmacovigilance office.

10. Clinical Pharmacist Verdict & Bottom Line

As a clinical pharmacist reviewing the totality of evidence surrounding Stelara 130 mg IV induction therapy, the following balanced assessment emerges:

Key Clinical Advantages ✅

• Dual-pathway cytokine inhibition: Simultaneous blockade of IL-12 and IL-23 provides broader anti-inflammatory coverage than single-target biologics, translating into robust mucosal healing rates.
• Superior immunogenicity profile: Anti-drug antibody formation rates are significantly lower than those observed with chimeric anti-TNF agents (e.g., infliximab), reducing the risk of secondary loss of response.
• Convenient long-term regimen: After a single hospital-based IV infusion, patients transition to self-administered SC injections every 8–12 weeks — one of the least burdensome maintenance schedules among IBD biologics.
• Favourable safety signal: Lower rates of serious opportunistic infections and malignancy compared to the anti-TNF class, making it a preferred option for patients with elevated baseline infection risk.

Notable Limitations ❌

• Substantial upfront cost: The multi-vial induction dose represents a significant financial burden that necessitates insurance pre-approval or government subsidy in most markets.
• Complex preparation logistics: Weight-based dose calculation, aseptic dilution, volume displacement, and filtered IV administration require a fully equipped hospital pharmacy and trained infusion nursing staff.
• Mandatory pre-screening: Latent TB testing (IGRA or TST), hepatitis B/C serology, complete blood count, and baseline liver function tests are obligatory before the first infusion, adding time and cost to the initiation pathway.

Bottom Line: Stelara 130 mg IV induction represents a gold-standard entry point for biologic therapy in adults with moderate-to-severe Crohn’s disease or ulcerative colitis who have failed or cannot tolerate conventional and anti-TNF treatments. Its combination of deep mechanistic targeting, durable clinical response, and a manageable long-term safety profile positions it among the most evidence-backed therapeutic options in the modern IBD armamentarium. Initiation must always occur under specialist gastroenterology supervision with full infectious disease screening.

❓ Frequently Asked Clinical Questions